141 related articles for article (PubMed ID: 35075635)
1. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
Avivi I; Luttwak E; Saiag E; Halperin T; Haberman S; Sarig A; Levi S; Aharon A; Herishanu Y; Perry C
Br J Haematol; 2022 Mar; 196(6):1329-1333. PubMed ID: 35075635
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Perry C; Luttwak E; Balaban R; Shefer G; Morales MM; Aharon A; Tabib Y; Cohen YC; Benyamini N; Beyar-Katz O; Neaman M; Vitkon R; Keren-Khadmy N; Levin M; Herishanu Y; Avivi I
Blood Adv; 2021 Aug; 5(16):3053-3061. PubMed ID: 34387648
[TBL] [Abstract][Full Text] [Related]
3. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
5. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
8. The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
Gueguen M; Khatchatourian L; Lohéac C; Dorval I; Mercier M; Le Calloch R; Mahé K; Rizcallah MJ; Hutin P; Fangous MS; Saidani N; Le Clech L
Infect Dis Now; 2022 Aug; 52(5):280-285. PubMed ID: 35667558
[TBL] [Abstract][Full Text] [Related]
9. Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients.
Fattizzo B; Bortolotti M; Rampi N; Cavallaro F; Giannotta JA; Bucelli C; Cassin R; Da Vià MC; Galassi G; Noto A; Pettine L; Rossi FG; Sciumè M; Ceriotti F; Consonni D; Barcellini W; Baldini L
Front Immunol; 2022; 13():852158. PubMed ID: 35634287
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
11. Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients.
Shashar M; Nacasch N; Grupper A; Benchetrit S; Halperin T; Erez D; Rozenberg I; Shitrit P; Sela Y; Wand O; Cohen-Hagai K
Am J Nephrol; 2022; 53(2-3):207-214. PubMed ID: 35172312
[TBL] [Abstract][Full Text] [Related]
12. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Gurion R; Rozovski U; Itchaki G; Gafter-Gvili A; Leibovitch C; Raanani P; Ben-Zvi H; Szwarcwort M; Taylor-Abigadol M; Dann EJ; Horesh N; Inbar T; Tzoran I; Lavi N; Fineman R; Ringelstein-Harlev S; Horowitz NA
Haematologica; 2022 Mar; 107(3):715-720. PubMed ID: 34320790
[TBL] [Abstract][Full Text] [Related]
13. Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.
Saito M; Mori A; Ishio T; Kobayashi M; Tsukamoto S; Kajikawa S; Yokoyama E; Kanaya M; Izumiyama K; Muraki H; Morioka M; Kondo T
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543695
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Diamantopoulos PT; Kontandreopoulou CN; Stafylidis C; Vlachopoulou D; Giannakopoulou N; Vardaka M; Mpouhla A; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ann Hematol; 2022 Dec; 101(12):2711-2717. PubMed ID: 36271935
[TBL] [Abstract][Full Text] [Related]
16. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment.
Tvito A; Ronson A; Ghosheh R; Kharit M; Ashkenazi J; Magen S; Broide E; Benayoun E; Rowe JM; Ofran Y; Ganzel C
Exp Hematol; 2022 Mar; 107():20-23. PubMed ID: 34952139
[TBL] [Abstract][Full Text] [Related]
18. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Role of the Research Nurse.
Buttiron Webber T; Provinciali N; Briata IM; Boitano M; Defferrari C; Magnani M; Paciolla F; Mercenaro E; Cevasco I; Gandini S; DeCensi A
Prof Inferm; 2021; 74(4):261. PubMed ID: 35363969
[TBL] [Abstract][Full Text] [Related]
19. Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors.
Pietroluongo E; De Placido P; Tortora M; Martinelli C; Viggiano A; Saponaro MR; Caltavituro A; Buonaiuto R; Morra R; Ottaviano M; Del Deo V; Cernera G; Gelzo M; Malfitano AM; Di Tolla MF; De Angelis C; Arpino G; Terracciano D; Bianco R; Veneziani BM; Formisano P; Castaldo G; Palmieri G; De Placido S; Giuliano M
J Thorac Oncol; 2023 Oct; 18(10):1399-1407. PubMed ID: 37390981
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
